KTKoichi Tanaka

Koichi Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Koichi Tanaka has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Tetsuya Kiuchi

    3 shared publications
  • Mikiko Ueda

    Department of Transplantation and Immunology and Horizontal Medical Research Organization, Transplant Tolerance Unit, Kyoto University, Faculty of medicine, Kyoto, Japan

    2 shared publications
  • Satoshi Kaihara

    2 shared publications
  • Yasuhiro Ogura

    Department of Transplantation Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan

    2 shared publications
  • Atsushi Ito

    Department of Transplantation and Immunology and Horizontal Medical Research Organization, Transplant Tolerance Unit, Kyoto University, Faculty of medicine, Kyoto, Japan

    1 shared publication
  • Atsushi Yoshizawa

    Department of Transplantation and Immunology and Horizontal Medical Research Organization, Transplant Tolerance Unit, Kyoto University, Faculty of medicine, Kyoto, Japan

    1 shared publication

Latest Publications

  • Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation

    by Koichi Tanaka, John Lake, Federico Villamil, Gary Levy, Paul Marotta, Sergio Mies, Bernard de Hemptinne, Christian Moench

    New immunosuppressive agents and regimens should be evaluated specifically in living donor liver transplant patients due to potential clinical and pharmacokinetic differences between deceased donor and living donor transplant recipients. The analysis presented here is the first direct comparison of clinical outcomes using cyclosporine microemulsion (CsA-ME) with monitoring of blood concentration at 2 hours postdose (C2) and tacrolimus-based immunosuppression in living donor liver transplantation. The analysis was conducted on the data provided by the 39 recipients of a living donor transplant out of the 495 patients enrolled in a 6-month, randomized, prospective, multicenter, open-label study (LIS2T). Patients were randomized to CsA-ME (C2 monitoring) or tacrolimus (monitoring of predose trough drug blood level [C0)]) and were administered corticosteroids with or without azathioprine. Twenty-three living-donor patients received CsA-ME and 16 received tacrolimus. By month 6, 9% of patients receiving CsA-ME and 19% of those receiving tacrolimus had lost their graft or died (not significant [NS]). Nine episodes of biopsy-proven acute rejection were reported: 4 in the CsA-ME group (17%) and 5 in the tacrolimus cohort (31%, NS). There were no significant differences in any safety parameter between groups. The most frequently reported serious adverse events were infections, which occurred in 14 patients in the CsA-ME group (61%) and 13 patients in the tacrolimus arm (81%, NS). Twelve patients in the CsA-ME arm (52%) and 5 in the tacrolimus arm (31%, NS) discontinued the study prematurely. In conclusion, CsA-ME C2 monitoring or tacrolimus both offer effective protection against rejection in living donor liver transplants while maintaining a good safety profile. (Liver Transpl 2005;11:1395–1402.)


  • Open Access

    Analyses of Peripheral Blood Mononuclear Cells in Operational Tolerance After Pediatric Living Donor Liver Transplantation

    by Ying Li, Takaaki Koshiba, Atsushi Yoshizawa, Yukihide Yonekawa, Kosuke Masuda, Atsushi Ito, Mikiko Ueda, Takahide Mori, Hiroshi Kawamoto, Yoshimasa Tanaka, et al.


  • Living donor liver transplantation: Eastern experiences

    by K. Tanaka, Y. Ogura, T. Kiuchi, Y. Inomata, S. Uemoto, H. Furukawa

    Liver transplantation became well established in Western countries in the 1980s, following the introduction of cyclosporine in 1979 [ 1 x 1 Calne, R.Y., Rolles, K., White, D.J. et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979; 2: 1033–1036 Abstract | PubMed | Scopus (713) | Google Scholar See all References , 2 x 2 Starzl, T.E., Klintmalm, G.B., Porter, K.A., Iwatsuki, S., and Schroter, G.P. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med. 1981; 305: 266–269 Crossref | PubMed | Scopus (316) | Google Scholar See all References ]. The number of liver transplant candidates rapidly increased throughout this period, leading to a serious shortage of grafts in many transplant centres in Europe and the USA. Conversely, many Asian countries did not see the introduction of cadaveric organ transplantation until the 1990s, due to issues as varied as religious and ethical opposition, debate over the definition of brain death, and public opinion. To overcome these obstacles, living donor liver transplantation (LDLT) was introduced in Japan, and spread to Korea, Taiwan, Hong Kong and other Asian countries. The LDLT technique has recently been re‐evaluated and has become an important option for end‐stage liver disease even in countries where cadaveric liver transplantation has long been utilised.


  • Open Access

    "Small-for-size Graft" and "Small-for-size Syndrome" in Living Donor Liver Transplantation

    by Koichi Tanaka, Yasuhiro Ogura

    Tanaka K, et al. Yonsei Med J. 2004 Dec;45(6):1089-1094. http://dx.doi.org/10.3349/ymj.2004.45.6.1089


  • Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases1

    by Taro Nakamura, Koichi Tanaka, Tetsuya Kiuchi, Mureo Kasahara, Fumitaka Oike, Mikiko Ueda, Satoshi Kaihara, Hiroto Egawa, Ilgin Ozden, Nobuaki Kobayashi, et al.

    Anatomical variations in right liver lobe are common. However, clinical implications and surgical management of these variations in living donor liver transplantation have not been analyzed systematically. Surgical anatomy of vascular and biliary structures in 120 right lobe grafts were reevaluated by reviewing the results of preoperative (computerized tomography and Doppler ultrasonography) and intraoperative (cholangiography) imaging as well as surgical findings. The data were analyzed in relation to surgical management of anatomical variations. The incidence of variants leading to multiple portal vein anastomoses was 7.5%. The incidence of dual right hepatic veins was 0.8%; 30% of the grafts had significant accessory hepatic veins (>5 mm) and 13.9% of these were multiple. All of them were successfully reconstructed with technical modifications including venoplasty and venous grafts, except for two cases with multiple intraparenchymal portal vein branches to the anterior segment. The incidence of dual hepatic arteries was 1.7%, but only one of them was reconstructed without negative sequelae. The incidence of variants potentially leading to multiple bile duct anastomoses was 35.0%, and eventually 39.2% of the grafts had multiple orifices. With a variety of techniques including ductoplasty, hepaticohepaticostomy, and biliary stent, total incidence of leakage and stenosis was 10.8% and 9.2%, respectively. Although ductoplasty, internal stent or no stenting, seemed to be associated with increased risk of complications, anatomical variants, multiple bile ducts, and duct-to-duct reconstruction did not bear a significant risk. Anatomical variations of vascular and biliary structures in right lobe grafts are common. However, most can be managed safely with technical modifications. Only cases with intraparenchymal origin of the anterior portal vein(s) may form a relative contraindication, especially when combined with similar biliary variants. Otherwise, intraoperative assessment of biliary anatomy was enough for successful management. Detailed and precise assessment of vascular and biliary anatomy is vital for appropriate surgical management.


  • Open Access

    Hepatic grafts from live donors: donor morbidity for 470 cases of live donation

    by Shiro Fujita, Il-Deok Kim, Kenji Uryuhara, Katsuhiro Asonuma, Hiroto Egawa, Tetsuya Kiuchi, Michihiro Hayashi, Shinji Uemeto, Yukihiro Inomata, Koichi Tanaka

    Living donor‐morbidity was evaluated in 470 consecutive cases of living donor liver transplantation carried out from June 1990 to May 1999 at Kyoto University. Grafting was categorized into 4 groups according to the resection lines; left lateral segmentectomy (S2 + 3, n= 282, R1), extended left lateral segmentectomy without middle hepatic vein (MHV) (S2 + 3 + part4, n= 45, R2), left lobectomy with MHV (S2 + 3 + 4, n= 99, R3) and right lobectomy without MHV (S5 + 6 + 7 + 8, n= 43, R4). Intraoperative blood loss and operation duration were less for left lateral segmentectomy, but no significant difference was observed between left lobectomy and right lobectomy. The length of postoperative hospital stays was comparable among all groups except for the group with right lobe grafting. The AST values at the peak and at POD 7 were significantly elevated for right lobectomy, but the AST value normalized within one month in the majority of the cases. The close follow‐up of donors with more than 1000 ml intraoperative bleeding, and of those donors who stayed in hospital for more than 30 days, the close follow‐up, furthermore, of those donors with AST values higher than 100 IU/L AST after one month, revealed complete recovery. Biliary leakage was the most common and annoying complication after donor operations, especially in for right lobe grafting, but all donors recovered completely with conservative or minimal invasive therapy. The two cases of re‐operation due to adhesive mechanical ileus we encountered were resolved completely. Finally, no donor‐operation related death was noted. In conclusion, the morbidity of living donors is low or minimal even for right lobectomy, the most extended procedure, and complete recovery can be expected in all cases.